Introduction
Gamma (γ)-amino-butyric acid (GABA) is the primary inhibitory neurotransmitter in adult human brain. During early development stages GABA plays both inhibitory and excitatory roles. GABA is created by decarboxylation of glutamic acid, a main excitatory neurotransmitter. There is evidence that GABA level is elevated in bipolar disorder (BP) [1] and impairment of genes involved in GABA metabolism has been linked to neuropsychiatric disorders such as epilepsy, autism and schizophrenia (SZ).
GABA interneurons
GABA producing (GABAergic) interneurons are the only source of GABA and the main source of inhibition in the mammalian central nervous system. GABAergic interneurons control the activity of pyramidal neurons and are responsible for the balance between excitation and inhibition signals in the brain. Depending on the brain region, they constitute 10-25% of the total number of cortical neurons. At least 20 different cortical subtypes and 21 hippocampal subtypes of GABAergic interneurons have been identifi ed [2] [3] [4] . GABAergic neurons of the hippocampus are arising before the glutamatergic neurons [5] . They may play a role in the development of the hippocampus in a manner analogous to Cajal-Retzius cells [6] . There is evidence that differentiation of the GABAergic phenotype depends on activity of Dlx genes (Dlx1/2). Loss of Dlx function eliminates hippocampal GABAergic neurons [7] .
Genes involved in GABA metabolism (synthesis, transport and decay) GABA synthesis is controlled by two glutamic acid decarboxylases (GADs) -GAD67/65 encoded by GAD1/2, respectively. The two genes produce a number of alternative transcripts. As GADs are not expressed in the astrocytes these cells cannot synthesize GABA from glutamic acid. This process is possible after transforming glutamate into glutamine (in reaction catalysed by glutamine synthetase) which is then transferred by specifi c transporter to presynaptic terminal containing GADs [8] . Diminished level of GADs was observed in cortex of autistic persons [9] . GABA loaded into synaptic vesicles by the vesicular GABA transporter (encoded by SLC32A1) is secreted by exocytosis into the synaptic cleft. GABA inactivation is performed by reuptake into presynaptic membrane or into astrocyte controlled by GABA transporters: GAT-1,GAT-2, GAT-3 and BGT-1, depended on Na
In human cortex GAT-1 and GAT-3 transporters are expressed. Decomposition of GABA depends on activity of GABA transaminase.
The GABA receptors GABAergic neurotransmission is mediated by GABA receptors. There are fast receptors: GABA A and GABA C which are ionotropic Cl -channels and slow onesmetabotropic GABA B G protein-coupled receptor. GABA A is the only GABA receptor whose subunit (α3) pre-mRNA is edited by adenosine deaminase [10] . This modifi cation diminishes Cl -current through the receptor [11] . GABA B plays a role of autoreceptor which inhibits neurotransmitter release through inhibition of calcium channels. Postsynaptically located GABA B produces slow inhibitory potentials through G proteincoupled inward rectifying potassium channels. GABA receptors are involved in the pathogenesis of absence and temporal lobe epilepsies, autism and SZ [12, 13] .
The GABA transaminase GABA transaminase (GABA-T) acts as a dimer protein in the mitochondrial matrix (monomer contains 500 amino acids). GABA-T catalyses amino group transfer from GABA to alpha-ketoglutarate using pyridoxal phosphate as a cofactor. This process generates glutamate and succinic semialdehyde which after converting to succinic acid is utilized by Krebs cycle. GABA-T locates to the 4-aminobutyrate aminotransferase gene -ABAT at chromosome 16p13.2. Genetic disorder associated with ABAT is GABA-T defi ciency. This is unique recessive disorder (only three cases described) whose symptoms (severe early infantile epileptic encephalopathy and growth acceleration) are evoked by cerebral accumulation of GABA [14] . The diagnosis based on measuring of cerebral GABA concentrations may be performed non-invasively by magnetic resonance spectroscopy [15] . Recent fi ndings reveal that GABA-T is also involved in the conversion of dNDP to dNTP within mitochondria and every case of GABA-T defi ciency is associated with mitochondrial DNA depletion syndrome [16] .
The role of GABA -inhibition and excitation 
Epigenetic regulation of GABAergic genes
Recent study in SZ and BP point to a downregulation in the expression of several genes in GABAergic interneurons very probably caused by gene promoter hypermethylation mediated by overexpression of DNA methyltransferases (DNMTs) in these cells. DNMTs catalyze the transfer of a methyl group from the methyl donor S-adenosylmethionine (SAM) to the carbon 5' of cytosines embedded in cytosine phosphodiester guanine (CpG) islands of many gene promoters. SZ and BP disorder could be associated with the epigenetic downregulation of genes expressed in GABAergic neurons:
GAD67and reelin -an extracellular large (400 kDa) The ALDH5A1 associated disorder -SSADH defi ciency identifi ed in hundreds of persons worldwide is much more common than GABA-T defi ciency. In the absence of SSADH succinic semialdehyde is reduced by 4-hydroxybutyrate dehydrogenase to gamma hydroxybutyric acid which is a potential neurotoxic agent. SSADH defi ciency symptoms are: early hypotonia and developmental delays, later expressive language impairment and obsessive-compulsive disorder, nonprogressive ataxia, hyporeflexia, and epilepsy [14] . The mutations of MECP2 protein (that binds to methylated DNA during transcriptional silencing) are cause of Rett syndrome -an X-linked disorder associated with motor impairment and autism-like symptoms. MeCP2 defi ciency in GABAergic neurons is associated with reduced GAD67/65 (GAD1/2) levels leading to reduction in presynaptic GABA release. This suggests that impairment of GABA synthesis may be responsible for neuropsychiatric symptoms in Rett syndrome [21] .
